Aim. To identify aggressively behaving classical Hodgkin lymphoma (CHL) of mediastinum and primary mediastinal B-cell lymphoma (PMBCL) and to classify them as mediastinal gray zone lymphoma(MGZL) and to define a minimum immunopanel for the diagnosis of MGZL. Materials and Methods. Ninety-two mediastinal B-cell lymphomas were reviewed with a wide immunopanel and were classified as CHL, PMBCL, or MGZL. CHL with an expression of 3 or 4 transcription factors performed worse, and hence the CHL with ≥3 transcription factors were classified as MGZL-CHL. In PMBCL, the cases with a weak or negative CD20 and positive CD15 as well as those cases showing cyclin E positivity with a negative or focal LCA and any one of the transcription factors were classified as MGZL-PMBCL. Results. The MGZL cases expanded from 9 to 28 cases after using an extended immunopanel. CHL and PMBCL had a disease-free survival rate of 86.8% and 69.2% and an overall survival rate of 97.4% and 80.8%, respectively. MGZL-CHL and MGZL-PMBCL had a disease-free survival rate of 33% and 40% and an overall survival rate of 66.7% and 60%, respectively. Conclusion. Thus, the MGZL may be a wider category than we think and hence the use of a wide immunopanel is recommended to identify the aggressively behaving mediastinal B-cell lymphomas.
EberleFCRodriguez-CanalesJWeiL. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin’s lymphoma and primary mediastinal large B-cell lymphoma. Haematologica. 2011;96:558-566.
2.
DunleavyKGrantCEberleFCPittalugaSJaffeESWilsonWH. Gray zone lymphoma: better treated like Hodgkin lymphoma or mediastinal large B-cell lymphoma?Curr Hematol Malig Rep. 2012;7:241-247.
3.
SwerdlowSHCampoEHarrisNL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
4.
ColbyTVHoppeRTWarnkeRA. Hodgkin’s disease: a clinicopathologic study of 659 cases. Cancer. 1982;49:1848-1858.
5.
PileriSAAscaniSLeonciniL. Hodgkin’s lymphoma: the pathologist’s viewpoint. J Clin Pathol. 2002;55:162-176.
6.
McCuneRCSyrbuSIVasefMA. Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin’s and non-Hodgkin’s lymphomas: a comparative study using high throughput tissue microarrays. Mod Pathol. 2006;19:1010-1018.
7.
UherovaPValdezRRossCWSchnitzerBFinnWG. Nodular lymphocyte predominant Hodgkin lymphoma. An immunophenotypic reappraisal based on a single-institution experience. Am J Clin Pathol. 2003;119:192-198.
8.
Quintanilla-MartinezLde JongDde MascarelA. Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France. J Hematop. 2009;2:211-236.
9.
RudigerTJaffeESDelsolG. Workshop report on Hodgkin’s disease and related diseases (‘grey zone’ lymphoma). Ann Oncol. 1998;9(suppl 5):S31-S38.
10.
SchweringIBrauningerAKleinU. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003;101:1505-1512.
11.
KuppersRYahalomJJostingA. Advances in biology, diagnostics, and treatment of Hodgkin’s disease. Biol Blood Marrow Transplant. 2006;12:66-76.
12.
ManiHJaffeES: Hodgkin lymphoma: an update on its biology with new insights into classification. Clin Lymphoma Myeloma. 2009;9:206-216.
13.
Quintanilla-MartinezLFendF. Mediastinal gray zone lymphoma. Haematologica. 2011;96:496-499.
14.
WilsonWHPittalugaSNicolaeA. A prospective study of mediastinal gray-zone lymphoma. Blood. 2014;124:1563-1569.
15.
TorlakovicETierensADangHDDelabieJ. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin’s disease. Am J Pathol. 2001;159:1807-1814.
16.
SteinHMarafiotiTFossHD. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood. 2001;97:496-501.
17.
HertelCBZhouXGHamilton-DutoitSJJunkerS. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene. 2002;21:4908-4920.
18.
ReDMuschenMAhmadiT. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res. 2001;61:2080-2084.
19.
SaezAIArtigaMJSanchez-BeatoM. Analysis of octamer-binding transcription factors Oct2 and Oct1 and their coactivator BOB.1/OBF.1 in lymphomas. Mod Pathol. 2002;15:211-220.
20.
BrownePPetrosyanKHernandezAChanJA. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol. 2003;120:767-777.
21.
LoddenkemperCAnagnostopoulosIHummelM. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol. 2004;202:60-69.
22.
Garcia-CosioMSantonAMartinP. Analysis of transcription factor OCT.1, OCT.2 and BOB.1 expression using tissue arrays in classical Hodgkin’s lymphoma. Mod Pathol. 2004;17:1531-1538.
23.
HoellerSZihlerDZlobecI. BOB. 1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin’s lymphoma from primary mediastinal large B-cell lymphoma. Histopathology. 2010;56:217-228.
24.
TorlakovicETorlakovicGNguyenPLBrunningRDDelabieJ. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol. 2002;26:1343-1350.
25.
FossHDReuschRDemelG. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin’s disease provides further evidence for its B-cell origin. Blood. 1999;94:3108-3113.
26.
DongHYBrownePLiuZGangiM. PAX-5 is invariably expressed in B-cell lymphomas without plasma cell differentiation. Histopathology. 2008;53:278-287.
27.
JundtFKleyKAnagnostopoulosI. Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood. 2002;99:3060-3062.
28.
PileriSAGaidanoGZinzaniPL. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol. 2003;162:243-253.
29.
OschliesIBurkhardtBSalaverriaI. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica. 2011;96:262-268.
30.
GualcoGNatkunamYBacchiCE. The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases. Mod Pathol. 2012;25:661-674.
31.
HimmelmannARivaAWilsonGLLucasBPTheveninCKehrlJH. PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. Blood. 1997;90:3984-3995.
32.
RodigSJSavageKJLaCasceAS. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol. 2007;31:106-112.
33.
RodigSJSavageKJNguyenV. TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas. Am J Surg Pathol. 2005;29:196-203.
34.
Traverse-GlehenAPittalugaSGaulardP. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin’s lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29:1411-1421.
35.
GarciaJFMollejoMFragaM. Large B-cell lymphoma with Hodgkin’s features. Histopathology. 2005;47:101-110.
36.
HsiEDSupSJAlemanyC. MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. Am J Clin Pathol. 2006;125:776-782.
37.
Copie-BergmanCGaulardPMaouche-ChretienL. The MAL gene is expressed in primary mediastinal large B-cell lymphoma. Blood. 1999;94:3567-3575.
38.
Copie-BergmanCPlonquetAAlonsoMA. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol. 2002;15:1172-1180.
39.
AndersonMWZhaoSFreudAG. CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am J Pathol. 2012;181:795-803.
40.
ZhaoSZhangHXingYNatkunamY. CD137 ligand is expressed in primary and secondary lymphoid follicles and in B-cell lymphomas: diagnostic and therapeutic implications. Am J Surg Pathol. 2013;37:250-258.
41.
DunleavyKPittalugaSMaedaLS. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368:1408-1416.
42.
LongoDLGlatsteinEDuffeyPL. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin’s disease. J Clin Oncol. 1997;15:3338-3346.
43.
ZinzaniPLMartelliMBertiniM. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica. 2002;87:1258-1264.
44.
RiegerMOsterborgAPettengellR. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol. 2011;22:664-670.
45.
ZinzaniPLMartelliMBendandiM. Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. Haematologica. 2001;86:187-191.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
